Εμφάνιση απλής εγγραφής

dc.creatorGkoutzourelas A., Liaskos C., Mytilinaiou M.G., Simopoulou T., Katsiari C., Tsirogianni A., Daoussis D., Scheper T., Meyer W., Bogdanos D.P., Sakkas L.I.en
dc.date.accessioned2023-01-31T07:43:13Z
dc.date.available2023-01-31T07:43:13Z
dc.date.issued2018
dc.identifier10.3389/fimmu.2018.02835
dc.identifier.issn16643224
dc.identifier.urihttp://hdl.handle.net/11615/72530
dc.description.abstractEpitope mapping of anti-Ro52 antibodies (Abs) has been extensively studied in patients with Sjögren's syndrome (SjS) and systemic lupus erythematosus (SLE). Comprehensive epitope mapping in systemic sclerosis (SSc), where anti-Ro52 antibodies are also frequently detected, has not been performed. The aim of the present study was to fully characterize Ro52 epitopes in anti-Ro52-positive SSc using Ro52 fragments spanning the full antigen. Further analysis was made according to anti-Ro60 status. Epitope mapping was performed in 43 anti-Ro52-positive SSc patients. Seventy eight anti-Ro52-positive pathological controls, including 20 patients with SjS, 28 patients with SLE, 15 patients with dermatomyositis (DM), and 15 patients with primary biliary cholangitis (PBC), and 20 anti-Ro52-negative healthy individuals as normal controls were also tested. Five recombinant Ro52 fragments [Ro52-1 (aa 1-127), Ro52-2 (aa 125-268), Ro52-3 (aa 268-475), Ro52-4 (aa 57-180), and Ro52-5 (aa 181-320) were used to test reactivity by line-immunoassay and in house ELISA. Anti-Ro60 reactivity was tested by ELISA. All anti-Ro52 positive sera reacted with Ro52-2; none recognized Ro52-3. Antibodies against Ro52-1 were less frequently found in SSc than in SjS/SLE (11.6 vs. 41.7%, p = 0.001); and antibodies against Ro52-4 were less frequently found in SSc than in SjS/SLE (27.9 vs. 50%, p = 0.03). In SSc patients, reactivity against Ro52-1 was more frequent in anti-Ro52+/anti-Ro60+ than in anti-Ro52+/anti-Ro60-patients (33.3 vs. 0%, p = 0.003). In this comprehensive analysis of Ro52 epitope mapping in SSc, the coiled coil domain remains the predominant epitope on Ro52. Contrary to SjS and SLE, patients with SSc fail to identify epitopic regions within the N-terminus of the protein, especially if they lack con-current anti-Ro60 reactivity. © Copyright © 2018 Gkoutzourelas, Liaskos, Mytilinaiou, Simopoulou, Katsiari, Tsirogianni, Daoussis, Scheper, Meyer, Bogdanos and Sakkas.en
dc.language.isoenen
dc.sourceFrontiers in Immunologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85058907510&doi=10.3389%2ffimmu.2018.02835&partnerID=40&md5=34729a49fc40ad139c26f601a1f98414
dc.subjectautoantibodyen
dc.subjectautoantigenen
dc.subjectepitopeen
dc.subjectribonucleoproteinen
dc.subjectsmall cytoplasmic RNAen
dc.subjectSS-A antigenen
dc.subjectTROVE2 protein, humanen
dc.subjectadulten
dc.subjectageden
dc.subjectepitope mappingen
dc.subjectfemaleen
dc.subjecthumanen
dc.subjectimmunologyen
dc.subjectmaleen
dc.subjectmiddle ageden
dc.subjectpathologyen
dc.subjectprotein domainen
dc.subjectsystemic sclerosisen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAutoantibodiesen
dc.subjectAutoantigensen
dc.subjectEpitope Mappingen
dc.subjectEpitopesen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectProtein Domainsen
dc.subjectRibonucleoproteinsen
dc.subjectRNA, Small Cytoplasmicen
dc.subjectScleroderma, Systemicen
dc.subjectFrontiers Media S.A.en
dc.titleAnti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosisen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής